Clinical trials: Ductal Carcinoma in Situ, active
Early Breast Cancer, Ductal Breast Carcinoma In Situ
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
- Trial name
- HFCBB (NCT06984250)
- Testing
- Hypofractionated Radiation Therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 315 people
- Sponsor
- National Taiwan University Hospital
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
This randomized phase II trial studies how well hypofractionated radiation therapy (RT) works compared to standard RT in treating patients with ductal breast carcinoma in situ (DCIS) or early invasive breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v6, Stage IA Breast Cancer AJCC v7
- Trial name
- NCT01266642
- Testing
- External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 301 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)
NRG-CC016 is being done to determine if omission of radiation therapy (RT) for patients with biosignature Low Risk (DCISionRT score less than 2.8) DCIS yields no clinically meaningful increase ipsilateral breast recurrence (IBR)…
- Trial name
- ABCD RT (NCT07554573)
- Testing
- Radiation Therapy, Standard of Care Radiation Therapy, No Intervention
- Volunteers
- 5,270 people
- Sponsor
- NRG Oncology
Ductal Carcinoma in Situ of the Breast
Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial
This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received…
- Trial name
- ASAIN (NCT07245316)
- Testing
- Avoiding surgery
- Where
- South Korea
- Volunteers
- 340 people
- Sponsor
- Jeong Eon Lee
Breast Atypical Hyperplasia, Breast Carcinoma
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer.
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05941520
- Testing
- Acolbifene Hydrochloride, Biospecimen Collection, Mammography
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Carcinoma in Situ, Breast Cancer
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
This study will investigate a novel approach to marking surgical cavity margins following tumor resection, to allow for more accurate radiotherapy following oncoplastic surgery.
- Trial name
- NCT06903468
- Testing
- Novel cavity marking technique
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Breast Cancer
Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.
- Trial name
- BONBIS (NCT00907868)
- Testing
- partial breast irradiation, whole breast irradiation
- Where
- France
- Volunteers
- 2,004 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Neoplasms
Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
To investigate clinical outcomes, late side effects, and cosmetic results of a single-fraction very accelerated partial breast irradiation as postoperative local treatment for the treatment of early stage breast cancer.
- Trial name
- sfVAPBI (NCT07067437)
- Testing
- single-fraction very accelerated partial breast irradiation
- Where
- 23 sites in France, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- National Institute of Oncology, Hungary
Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
CAN1012 in Pre-Malignant DCIS and LCIS
This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.
- Trial name
- NCT07408856
- Testing
- CAN1012
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Providence Health & Services
Breast Carcinoma, Breast Ductal Carcinoma in Situ
A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
This clinical trial evaluates a patient navigation program for addressing disparities in breast cancer care. The navigation program is designed to help improve patient knowledge about clinical and supportive care services…
- Trial name
- NCT06350500
- Testing
- Patient Navigation, Questionnaire
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Roswell Park Cancer Institute
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
This phase II trial studies the effect of calorie reduction while undergoing stereotactic ablative radiation therapy in treating patients with breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8
- Trial name
- NCT04959474
- Testing
- Best Practice, Stereotactic Body Radiation Therapy, Resection
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Thomas Jefferson University
Carcinoma, Intraductal, Noninfiltrating
Multimodal Imaging With FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer
DCIS (ductal carcinoma in situ) is a common pre-stage for breast cancer. The goal of this clinical trial is to learn if FAPI-PET/MRI (an imaging technique with a weakly radioactive drug) helps to diagnose hidden invasive breast…
- Trial name
- MI-CISDIR (NCT06540872)
- Testing
- [68Ga]Ga-FAPI-46
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Universität Münster
Ductal Carcinoma in Situ
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the…
- Trial name
- NCT06075953
- Testing
- Tamoxifen, Exemestane, Letrozole
- Where
- 30 sites in United States
- Volunteers
- 400 people
- Sponsor
- QuantumLeap Healthcare Collaborative
DCIS, Breast Cancer
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed…
- Conditions
- DCIS, Breast Cancer, Breast Neoplasms, Sentinel Lymph Node
- Trial name
- SENTINOT_2 (NCT04722692)
- Testing
- Delayed SLND, Late SLND
- Where
- 9 sites in United States, Hong Kong and 1 more
- Volunteers
- 500 people
- Sponsor
- Uppsala University
Ductal Carcinoma in Situ, Extensive Disease
Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most…
- Conditions
- Ductal Carcinoma in Situ, Extensive Disease, Mastectomy
- Trial name
- HORNEO01 (NCT04666961)
- Testing
- Tamoxifen 20 mg, Anastrozole 1Mg Tab
- Where
- 8 sites in France
- Volunteers
- 262 people
- Sponsor
- Institut Cancerologie de l'Ouest
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited…
- Conditions
- Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma
- Trial name
- NCT05053152
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 245 sites in United States, Canada
- Volunteers
- 194 people
- Sponsor
- NRG Oncology
Prostate Cancer, Prostate Intraductal Carcinoma
Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer
The aim of this clinical trial is whether artificial intelligence models can be used for accurate clinical preoperative diagnosis and postoperative diagnosis of pathological findings, and will also measure the accuracy of the…
- Conditions
- Prostate Cancer, Prostate Intraductal Carcinoma, Prostate Cancer Aggressiveness, Prostate Cancer Stage
- Trial name
- NCT06662708
- Testing
- Accurate Prediction Artificial Intelligence Models
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shao Pengfei
Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm
Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up
The aim of the study is to evaluate whether tamoxifen at a low dose of 5mg/d reduces in the long term the incidence of invasive breast cancer and ductal carcinoma in situ, DCIS (DIN 1c, 2, 3) of the breast, in woman operated for…
- Conditions
- Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm, Breast Neoplasms, Atypical Hyperplasia
- Trial name
- TAM-01 (NCT01357772)
- Testing
- Tamoxifen
- Where
- 14 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Andrea DeCensi
Breast Cancer
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as standard per daily radiation therapy in treating breast cancer.
- Trial name
- NCT01349322
- Testing
- Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost
- Where
- 415 sites in United States, Canada and 6 more
- Volunteers
- 2,354 people
- Sponsor
- Radiation Therapy Oncology Group
DCIS, Breast Cancer
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast
Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate of in-breast recurrences (IBR) by more than…
- Conditions
- DCIS, Breast Cancer, Low Risk DCIS, Breast Conserving Surgery
- Trial name
- ROMANCE (NCT03878342)
- Testing
- Radiotherapy, No Radiotherapy
- Where
- 37 sites in France
- Volunteers
- 295 people
- Sponsor
- UNICANCER